Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Stefan Kaulfuss"'
Autor:
Anuhar Chaturvedi, Charu Gupta, Razif Gabdoulline, Nora M. Borchert, Ramya Goparaju, Stefan Kaulfuss, Kerstin Görlich, Renate Schottmann, Basem Othman, Julia Welzenbach, Olaf Panknin, Markus Wagner, Robert Geffers, Arnold Ganser, Felicitas Thol, Michael Jeffers, Andrea Haegebarth, Michael Heuser
Publikováno v:
Haematologica, Vol 106, Iss 2 (2020)
Mutant IDH1 (mIDH1) inhibitors have shown single-agent activity in relapsed/refractory AML, though most patients eventually relapse. We evaluated the efficacy and molecular mechanism of the combination treatment with azacitidine, which is currently t
Externí odkaz:
https://doaj.org/article/64b0bb93a8d94cbca64e4eba9c21cc0f
Autor:
Katharina J. Wenger, Christian Richter, Michael C. Burger, Hans Urban, Stefan Kaulfuss, Patrick N. Harter, Sridhar Sreeramulu, Harald Schwalbe, Joachim P. Steinbach, Elke Hattingen, Oliver Bähr, Ulrich Pilatus
Publikováno v:
Cancers, Vol 12, Iss 11, p 3175 (2020)
Background: BAY1436032 is a fluorine-containing inhibitor of the R132X-mutant isocitrate dehydrogenase (mIDH1). It inhibits the mIDH1-mediated production of 2-hydroxyglutarate (2-HG) in glioma cells. We investigated brain penetration of BAY1436032 an
Externí odkaz:
https://doaj.org/article/479efd8b03fb48afacc240f3c157bdf5
Autor:
Judith Günther, Roman C. Hillig, Katja Zimmermann, Stefan Kaulfuss, Clara Lemos, Duy Nguyen, Hartmut Rehwinkel, Matthew Habgood, Christian Lechner, Roland Neuhaus, Ursula Ganzer, Mark Drewes, Jijie Chai, Léa Bouché
Publikováno v:
Journal of Medicinal Chemistry. 65:14366-14390
The branched-chain amino acid transaminases (BCATs) are enzymes that catalyze the first reaction of catabolism of the essential branched-chain amino acids to branched-chain keto acids to form glutamate. They are known to play a key role in different
Autor:
Ghazaleh Tabatabai, Carol Peña, Michael Jeffers, Eleni Lagkadinou, Charles Cai, Stefan Kaulfuss, Markus Wagner, Simon Langer, Susanne Reschke, Christine Rentzsch, Catya Munhoz, Isabelle Genvresse, Cristiana Roggia, Kamalesh K. Sankhala, Ulrik Lassen, Katharina Wenger, Michael C. Burger, Joachim P. Steinbach, Wolfgang Wick, Yuichi Ando, Masafumi Ikeda, Heinz-Josef Lenz, Yoshitaka Narita, Volker Heinemann, David Schiff, Filip Janku, Sant P. Chawla, Kristoffer Rohrberg, Martin Schuler, Oliver Bähr, Antje Wick
Supplementary Figure S1. Geometric mean plasma concentration-time profiles of BAY1436032 at dose levels of 150 mg to 1500 mg.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1bab014a6e82bd086327f7b09d4b706
https://doi.org/10.1158/1078-0432.22479981.v1
https://doi.org/10.1158/1078-0432.22479981.v1
Autor:
Ghazaleh Tabatabai, Carol Peña, Michael Jeffers, Eleni Lagkadinou, Charles Cai, Stefan Kaulfuss, Markus Wagner, Simon Langer, Susanne Reschke, Christine Rentzsch, Catya Munhoz, Isabelle Genvresse, Cristiana Roggia, Kamalesh K. Sankhala, Ulrik Lassen, Katharina Wenger, Michael C. Burger, Joachim P. Steinbach, Wolfgang Wick, Yuichi Ando, Masafumi Ikeda, Heinz-Josef Lenz, Yoshitaka Narita, Volker Heinemann, David Schiff, Filip Janku, Sant P. Chawla, Kristoffer Rohrberg, Martin Schuler, Oliver Bähr, Antje Wick
Purpose:BAY1436032, an inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), was active against multiple IDH1-R132X solid tumors in preclinical models. This first-in-human study was designed to determine the safety and pharmacokinetics of BAY143603
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7438268b16ee6568428fa4555e04a50c
https://doi.org/10.1158/1078-0432.c.6530343.v1
https://doi.org/10.1158/1078-0432.c.6530343.v1
Autor:
Ghazaleh Tabatabai, Carol Peña, Michael Jeffers, Eleni Lagkadinou, Charles Cai, Stefan Kaulfuss, Markus Wagner, Simon Langer, Susanne Reschke, Christine Rentzsch, Catya Munhoz, Isabelle Genvresse, Cristiana Roggia, Kamalesh K. Sankhala, Ulrik Lassen, Katharina Wenger, Michael C. Burger, Joachim P. Steinbach, Wolfgang Wick, Yuichi Ando, Masafumi Ikeda, Heinz-Josef Lenz, Yoshitaka Narita, Volker Heinemann, David Schiff, Filip Janku, Sant P. Chawla, Kristoffer Rohrberg, Martin Schuler, Oliver Bähr, Antje Wick
Supplementary Table S12. NGS analysis of select tumor-associated genes in archival tumor tissue obtained from a subset of subjects.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0557c7ec6881acce6a375070dc55437b
https://doi.org/10.1158/1078-0432.22479969.v1
https://doi.org/10.1158/1078-0432.22479969.v1
Autor:
Ghazaleh Tabatabai, Carol Peña, Michael Jeffers, Eleni Lagkadinou, Charles Cai, Stefan Kaulfuss, Markus Wagner, Simon Langer, Susanne Reschke, Christine Rentzsch, Catya Munhoz, Isabelle Genvresse, Cristiana Roggia, Kamalesh K. Sankhala, Ulrik Lassen, Katharina Wenger, Michael C. Burger, Joachim P. Steinbach, Wolfgang Wick, Yuichi Ando, Masafumi Ikeda, Heinz-Josef Lenz, Yoshitaka Narita, Volker Heinemann, David Schiff, Filip Janku, Sant P. Chawla, Kristoffer Rohrberg, Martin Schuler, Oliver Bähr, Antje Wick
Supplementary Methods, Supplementary Results, Supplementary Tables S1-S11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130631a30eed0d3c7f2f65db7a13d540
https://doi.org/10.1158/1078-0432.22479984.v1
https://doi.org/10.1158/1078-0432.22479984.v1
Autor:
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Virendar Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd Golub
MCL1 is an anti-apoptotic protein that is frequently amplified in cancer and confers resistance to current standard of care. Therefore, MCL1 is an attractive anti-cancer target. Here we describe ANJ810 as a novel, potent, and selective MCL1 inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3370ddc437abc0844e20e4cc6988691c
https://doi.org/10.21203/rs.3.rs-2519986/v1
https://doi.org/10.21203/rs.3.rs-2519986/v1
Autor:
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pillari, Stephan Menz, Matthias Ocker, Brian Hubbard, Virendar Kaushik, Karl Ziegelbauer, Todd Golub
Publikováno v:
Cancer Research. 83:506-506
MCL1 is an anti-apoptotic protein inhibiting cancer cell death. It is frequently amplified or overexpressed in cancer and confers resistance to relevant standard of care. Therefore, MCL1 is an attractive target to potentially re-sensitize tumors to c
Autor:
Courtney D. DiNardo, Lewis R. Silverman, Charles Cai, Claudia D. Baldus, Isabelle Genvresse, Eleni Lagkadinou, Neil Palmisiano, Walter Fiedler, Alice S. Mims, Michael Jeffers, Markus Wagner, Ioannis Mantzaris, Alexander E. Perl, Gary Wilkinson, Bingyan Wu, Christine Rentzsch, Eunice S. Wang, Timothy S. Pardee, Sebastian Schwind, Stefan Kaulfuss, Michael Heuser, Alwin Krämer
Publikováno v:
Leukemia
The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses rang